RXL241220P107000
- 0.00
- 0.000.00%
Proshares Trust Pshs Ult Hlthcre Newsroom
Eli Lilly Announced Topline Results From The SURMOUNT-5 Phase 3b Open-label Randomized Clinical Trial
Trump's R&D policy ignites cash flow! These companies welcome a "financial spring"!
Trump's new policy on research and development may bring a "cash flow revolution" to usa companies! By allowing companies to record research and development expenses instantly, businesses can not only reduce their tax burden but also significantly enhance their liquidity.
UnitedHealth Group Introduces FY25 Guidance, Sees EPS $29.50-$30.00 Vs $29.92 Est.; Revenue $450B-$455B Vs $431.435B Est.
Mainz Biomed Announces Reverse Stock Split Soon After Collaborating With MedTech Giant Thermo Fisher Scientific
BeiGene Started at Overweight at Morgan Stanley on Brukinsa Market Share Growth
Check Out What Whales Are Doing With UNH
'ADA Advises Against Using Compounded GLP-1 RA Medications' - Medscape
Nasdaq, S&P Ebb Near Record Highs, Dow Slips as JOLTS Report Kicks off Run of Jobs Data
Amedisys Falls as Divestiture Buyer in Sale to UnitedHealth Has Legal Judgement Against It
Screening For Black Friday Bargains In The Stock Market
Weight Loss Drug Wars Heat Up: Amgen Challenges Eli Lilly, Novo's Dominance
Want To Bet On Ozempic, Wegovy Success? Defiance Introduces Leveraged ETF To Capture Novo Nordisk Momentum
Concerned about falling behind eli lilly and co, the novo-nordisk a/s india team is reportedly urging an early launch of Wegovy.
①It is reported that novo-nordisk a/s india team recently proposed to advance the market launch time to 2025, which is roughly the same as eli lilly and co's expected time for the launch of its weight loss drug Mounjaro; ②The novo-nordisk a/s india team stated that if Wegovy cannot be launched early in india, the company may lag behind eli lilly and co in this market.
Bank of America To Rally More Than 21%? Here Are 10 Top Analyst Forecasts For Tuesday
Ray Dalio's Bridgewater Adds Broadcom, Apple, SMCI In Q3, While Offloading Stake In AI Giant Nvidia And Other Big Tech Companies
Merck & Co Unusual Options Activity For December 02
Weight Loss Drugs Like Wegovy, Zepbound Linked To Reduced Alcohol Use: Study
Marjorie Taylor Greene Discloses Buys of AMD, Alphabet, Microsoft, Others
The strongest competitor's data is not good, will the 'weight-loss duo' continue to dominate?
Analysts believe that if Amgen's weight loss drug could achieve a 20% weight loss effect a few years ago, it would have been the best among similar products, but now Eli Lilly and Co and Novo-Nordisk A/S pipeline drugs may achieve or exceed a 25% weight loss effect. Currently, dozens of pharmaceutical companies are actively entering the weight loss drug market, but none have shown the potential to truly challenge the 'weight loss giants'.
Spotlight on AbbVie: Analyzing the Surge in Options Activity